drugset / Trial / NCT01795924
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether PD-616 in combination with low-dose Cytarabine is safe and effective in the treatment of untreated or relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Timeline
- Start
- 2013-01
- Primary completion
- 2014-09
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 12-O-tetradecanoylphorbol-13-acetate | Unknown | 0.0875 mg/m2 | Intravenous |
| Subject | 12-O-tetradecanoylphorbol-13-acetate | Unknown | 0.125 mg/m2 | Intravenous |
| Subject | 12-O-tetradecanoylphorbol-13-acetate | Unknown | 0.1625 mg/m2 | Intravenous |